You are here

SARC033

Active
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Type of Sarcoma: 
Epithelioid Hemangioendothelioma
Drug: 
Trametinib
Accrual Status: 
Not Recruiting
Overall Study Principal Investigator: 
Scott Schuetze, MD, PhD
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer Center EDDOP
 

For more information about this trial and open sites: